Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Concord Biotech Ltd - 543960 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, May 23, 2024 Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 ,inter alia, to consider and approve 1. Consider and approve the Standalone and Consolidated Audited Financial Results for the Fourth quarter and Year ended March 31, 2024 2. To consider other business matters along with Recommendation of Dividend, if any. 3. Any other Business Further, in continuation of our earlier letter dated April 01, 2024 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s Code of Conduct to Regulate, Monitor and Report trading by Designated Persons and their immediate relative, the trading window for dealing in the securities of the Company shall remain closed up to 48 hours after the declaration of the Financial Results of the Company for the fourth quarter and Financial Year ended March 31, 2024. You are requested to take the same on record.
15-05-2024
Bigul

Concord Biotech Ltd - 543960 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyConcord Biotech Ltd 2CIN NO.U24230GJ1984PLC007440 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 6.23 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Prakash Sajnani Designation: Asst Vice president Finance and CS EmailId: finance@concordbiotech.com Name of the Chief Financial Officer: Lalit Sethi Designation: Chief Financial Officer EmailId: lalitsethi@concordbiotech.com Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
25-04-2024
Bigul

Concord Biotech Ltd - 543960 - Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 For The Year Ended On 31St March, 2024

 Pursuant to regulation 7(3) of SEBI (LODR)Regulation, 2015, as amended from time to time, we hereby confirm that all activities in relation to both physical and electronic share transfer facility during the period from 01.04.2023 to 31.03.2024 (both days inclusive) are maintained by the Company''s Registrar & Share Transfer Agent viz., Link Intime India Private Limited, which is registered as Registrar and Share Transfer Agent in Category-I with SEBI via Registration No. INR000004058. Kindly take the same on record.
18-04-2024
Bigul

Concord Biotech Ltd - 543960 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015

 Pursuant to Regulation 40(9) of SEBI (LODR) Regulation, 2015, We have enclosed a copy of certificate dated 12th April, 2024, Issued by M/S Ashish Shah & Associates, Practicing Company Secretary for the year ended 31st March, 2024. We Request you to Kindly take the same on records
18-04-2024
Bigul

Concord Biotech Ltd - 543960 - Reply To Clarification Sought On Volume Movement

 We hereby submit that the company has disclosed all the material information/announcement or events from time to time to the exchange which may have bearing on the operation/performance of the company which includes all the necessary disclosures in accordance with regulation 30 of SEBI (LODR) regulation, 2015 and under insider trading regulation, have always been disclosed by the company within stipulated time and the same is available in public domain. There is no pending information or announcement which have a bearing on increase in volume of shares of the company. Therefore, the increase in volume of shares is purely due to market condition and absolutely market driven and the company is in no way connected with any such increase in volume. We hope the above clarifies and request you to kindly take the same on records.
15-04-2024
Bigul

Concord Biotech Ltd - 543960 - Clarification sought from Concord Biotech Ltd

 The Exchange has sought clarification from Concord Biotech Ltd on April 15, 2024, with reference to Movement in Volume. The reply is awaited.
15-04-2024
Bigul

Concord Biotech Ltd - 543960 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In compliance with regulation 74(5) of SEBI (depositories and Participants) regulations, 2018, as amended from time to time, we furnish herewith certificate dated 06.04.2024, issued by Link Intime India Private Limited, Registrar and Share transfer agent of the company for the quarter ended March 31, 2024. We request you to kindly take the same as record.
09-04-2024
Bigul

Concord Biotech Ltd - 543960 - Closure of Trading Window

 In terms of the provisions of the SEBI (Prohibition of Insider Trading) Regulation, 2015 and in compliance with the terms of Code of conduct, the "Trading Window" for dealing in the securities of the company will be closed for all designated persons and their immediate relatives with effect from 01/04/2024 and the same will remain closed till 48 hours after the announcement of financial results for the year and quarter ended on 31/03/2024 to the public. Accordingly, all designated persons of the company and their immediate relatives are advised not to trade in the securities of the company during the aforesaid purpose of closure of trading window. Kindly take the note of same.
01-04-2024
Bigul

Concord Biotech Ltd - 543960 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Intimation About EUGMP Certificate Issued By Government Of Upper Franconia For Dholka Facility (Unit I) Of The Company

 In compliance with the aforesaid regulation, we hereby notify that Government of Upper Franconia has Issued certificate of Good Manufacturing Practices (EUGMP) for our Unit 1 (API Facility) of the company, located at Trasad Road, Dholka-382225 in Ahmedabad, Gujarat. The certificate is issued for the product "Tacrolimus Premix 20%." Kindly take the above information on records.
22-03-2024
Bigul

Concord Biotech Ltd - 543960 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Intimation About GMP Certificate Issued By Brazilian Health Regulatory Agency (ANVISA) At Dholka Facility (Unit I) Of The Company.

 In compliance with the aforesaid regulation, we hereby notify that Brazilian Health Regulatory Agency (ANVISA) has issued a Certificate of Good Manufacturing Practices of our Unit 1 (API Facility) of the Company, Located at Trasad Road, Dholka-382225 in Ahmedabad, Gujarat. Kindly take the above information on record.
06-03-2024
Next Page
Close

Let's Open Free Demat Account